JP6836506B2 - 細菌性呼吸器感染症を処置するためのピオシン類の肺投与 - Google Patents

細菌性呼吸器感染症を処置するためのピオシン類の肺投与 Download PDF

Info

Publication number
JP6836506B2
JP6836506B2 JP2017535141A JP2017535141A JP6836506B2 JP 6836506 B2 JP6836506 B2 JP 6836506B2 JP 2017535141 A JP2017535141 A JP 2017535141A JP 2017535141 A JP2017535141 A JP 2017535141A JP 6836506 B2 JP6836506 B2 JP 6836506B2
Authority
JP
Japan
Prior art keywords
piocin
piosin
mice
treated
piocins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017535141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529398A5 (https=
JP2017529398A (ja
Inventor
ウォーカー，ダニエル
マッコーイー，ローラ
Original Assignee
ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー
ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー, ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー filed Critical ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー
Publication of JP2017529398A publication Critical patent/JP2017529398A/ja
Publication of JP2017529398A5 publication Critical patent/JP2017529398A5/ja
Application granted granted Critical
Publication of JP6836506B2 publication Critical patent/JP6836506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017535141A 2014-09-23 2015-09-22 細菌性呼吸器感染症を処置するためのピオシン類の肺投与 Active JP6836506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416788.6A GB201416788D0 (en) 2014-09-23 2014-09-23 Therapeutic applications for pyocins
GB1416788.6 2014-09-23
PCT/EP2015/071768 WO2016046218A1 (en) 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections

Publications (3)

Publication Number Publication Date
JP2017529398A JP2017529398A (ja) 2017-10-05
JP2017529398A5 JP2017529398A5 (https=) 2018-10-25
JP6836506B2 true JP6836506B2 (ja) 2021-03-03

Family

ID=51869352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017535141A Active JP6836506B2 (ja) 2014-09-23 2015-09-22 細菌性呼吸器感染症を処置するためのピオシン類の肺投与

Country Status (7)

Country Link
US (2) US11643442B2 (https=)
EP (1) EP3200813B1 (https=)
JP (1) JP6836506B2 (https=)
CN (1) CN107073073B (https=)
CA (1) CA2962117C (https=)
GB (1) GB201416788D0 (https=)
WO (1) WO2016046218A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857606B2 (en) 2017-12-14 2024-01-02 Bactoclear Holdings Pte. Ltd. Therapeutic bacteriocins
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
EP3957995A1 (en) * 2018-11-19 2022-02-23 Bioaster Methods and reagents for multiplex binding experiments
MX2021014984A (es) * 2019-06-06 2022-01-24 Nomad Bioscience Gmbh Klebicinas para el control de klebsiella.
EP4248987A1 (en) * 2022-03-21 2023-09-27 Nomad Bioscience GmbH Chimeric bacteriocins and method for the control of pseudomonas
CN121135834A (zh) * 2024-06-14 2025-12-16 无锡佰翱得生物科学股份有限公司 一种绿脓杆菌InA蛋白及其应用
CN121135836A (zh) * 2024-06-14 2025-12-16 无锡佰翱得生物科学股份有限公司 一种绿脓杆菌免疫蛋白及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861754A (en) 1986-05-28 1989-08-29 Farkas Himsley Hannah Bacteriocins and compositions thereof in anti-viral treatment
JP3655645B2 (ja) * 1992-02-28 2005-06-02 中外製薬株式会社 経粘膜投与剤
CA2242335A1 (en) 1996-11-15 1998-05-22 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2381755A1 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20060229244A1 (en) * 2004-09-27 2006-10-12 Robert Dorit Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections
ES2387722T3 (es) * 2006-05-15 2012-09-28 Avidbiotics Corporation Bacteriocinas modificadas y métodos para su uso
US7700729B2 (en) * 2006-05-15 2010-04-20 Avidbiotics Corporation Modified bacteriocins and methods for their use
WO2008002663A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs
US20080286236A1 (en) * 2007-05-14 2008-11-20 Avidbiotics Corporation Inhibition of yersinia pestis
JP6243325B2 (ja) * 2011-04-12 2017-12-06 ガンガゲン インコーポレーティッド キメラ抗菌ポリペプチド
GB201116234D0 (en) * 2011-09-20 2011-11-02 Aseptika Ltd Biomarkers for respiratory infection

Also Published As

Publication number Publication date
CN107073073A (zh) 2017-08-18
WO2016046218A1 (en) 2016-03-31
GB201416788D0 (en) 2014-11-05
US20230303636A1 (en) 2023-09-28
EP3200813A1 (en) 2017-08-09
CA2962117A1 (en) 2016-03-31
CA2962117C (en) 2023-04-25
US11643442B2 (en) 2023-05-09
EP3200813B1 (en) 2021-04-07
JP2017529398A (ja) 2017-10-05
US12162911B2 (en) 2024-12-10
CN107073073B (zh) 2021-07-09
US20170240602A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
JP6836506B2 (ja) 細菌性呼吸器感染症を処置するためのピオシン類の肺投与
Yanat et al. Plasmid-mediated quinolone resistance in Enterobacteriaceae: a systematic review with a focus on Mediterranean countries
Wang et al. A phage lysin fused to a cell-penetrating peptide kills intracellular methicillin-resistant Staphylococcus aureus in keratinocytes and has potential as a treatment for skin infections in mice
Feng et al. Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo
Chee et al. Epinecidin-1, an antimicrobial peptide derived from grouper (Epinephelus coioides): Pharmacological activities and applications
US20100254950A1 (en) Bacteriophage or lytic protein derived from the bacteriophage which effective for the treatment of staphylococcus aureus biofilm
ES2926129T3 (es) Terapia con fagos
JP6818349B2 (ja) アシネトバクター溶解素
CN112218659A (zh) 用于治疗葡萄球菌感染的治疗性噬菌体组合物
US20150164984A1 (en) Colicins for Treating Bacterial Infections
US11207378B2 (en) Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
JP2026031930A (ja) クレブシエラの制御のためのクレビシン
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
Safarpour-Dehkordi et al. A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections
Yacoub et al. Effect of Nk-lysin peptides on bacterial growth, MIC, antimicrobial resistance, and viral activities
CN110714000A (zh) 一种Toll样受体配体蛋白在抗细菌感染中的应用
CN100485038C (zh) 小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
JP2019510519A5 (https=)
HK1241754B (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
US20220193186A1 (en) Method of treating and preventing bone and joint infections
Lokesh et al. Phage as medicine for bacterial diseases
Odland IDWeek 2019
Odland IDWeek 2019. Washington, DC, USA-October 2-6, 2019
McGillivary et al. RSV-induced dysregulation of expression of a mucosal β-defensin augments colonization of the upper airway by nontypeable Haemophilus influenzae
WO2021211303A1 (en) Antiviral, bacteriophage-derived polypeptides and their use against viruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210205

R150 Certificate of patent or registration of utility model

Ref document number: 6836506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250